BiotechTube
Home/Pipeline/Perjeta (Pertuzumab) Biosimilar

Perjeta (Pertuzumab) Biosimilar

HER2‑positive Breast Cancer

Process Scale‑upActive

Key Facts

Indication
HER2‑positive Breast Cancer
Phase
Process Scale‑up
Status
Active
Company
NeuClone

About NeuClone

Australian biosimilar developer using a proprietary CHO platform to bring affordable biologics to market.

View full company profile

Therapeutic Areas

OncologyImmunologyBone HealthInfectious Diseases

Other HER2‑positive Breast Cancer Drugs

DrugCompanyPhase
Herceptin (Trastuzumab) BiosimilarNeuClonePhase 1
MagSense™ HER2 Imaging AgentImagion BiosystemsPhase 2
P-003Panacea BiotecPhase 3
Trastuzumab BiosimilarHeteroPhase 3
Legrand‑Herceptin BiosimilarLaboratorios LegrandCommercial
AfriMab-1Afrigen BiologicsPreclinical
Biosimilar TrastuzumabBiosidusCommercial
TrazherInnogene KalbiotechCommercial
MINC‑trastuzumabSuntec MedicalPreclinical